Moreover, edaravone shows consistent in-vivo efficacy to activate the GDNF/RET signaling in mouse spinal cord samples, justifying more studies in mouse models of ALS and other neurodegenerative diseases that may benefit from neuroprotection through GDNF/RET activation. This evidence concerns the gene RET and neurodegenerative disease.